Australian biotech firm Imugene partners with Kincell Bio for $6M to sell its cell therapy manufacturing facility, focusing on immuno-oncology therapies.

Imugene, an Australian biotech firm, partners with Kincell Bio for $6M to sell its cell therapy manufacturing facility. Imugene will focus on immuno-oncology therapies, while Kincell Bio utilizes the facility for continued growth and innovation. This strategic partnership aims to leverage Kincell Bio's expertise in cell therapy manufacturing for both companies' benefit.